Literature DB >> 6349019

Cefuroxime: antimicrobial activity, Pharmacology, and clinical efficacy.

B R Smith, J L LeFrock.   

Abstract

The antimicrobial activity, pharmacology, toxicity, and clinical efficacy of cefuroxime are reviewed. Cefuroxime has a second-generation cephalosporin spectrum of activity similar to cefamandole. Addition of a methoxyimino side chain has enhanced its beta-lactamase stability. Cefuroxime is active against certain cephalothin-, cefamandole-, and gentamicin-resistant bacteria. Cefuroxime has an extended half-life which allows dosing every 8 h. If penetrates into bodily tissues and fluids, including the cerebrospinal fluid, in therapeutic concentrations. Cefuroxime has been used successfully in the treatment of meningitis; sepsis; urinary tract, bone and joint, pulmonary, skin, and soft tissue infections; and gonorrhea. Competitive pricing of cefuroxime should provide a cost-effective substitute for cefamandole and, in certain situations, third-generation cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6349019

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  7 in total

Review 1.  Pharmacokinetics and tissue concentrations of cefuroxime.

Authors:  T B Vree; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

2.  Blood concentrations of cefuroxime in cardiopulmonary bypass surgery.

Authors:  Daphne Bertholee; Peter G J ter Horst; Michel L Hijmering; Alexander J Spanjersberg; Wobbe Hospes; Bob Wilffert
Journal:  Int J Clin Pharm       Date:  2013-06-21

3.  Comparison of single-dose cefuroxime axetil with ciprofloxacin in treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing Neisseria gonorrhoeae strains.

Authors:  E M Thorpe; J R Schwebke; E W Hook; A Rompalo; W M McCormack; K L Mussari; G C Giguere; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

4.  Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections.

Authors:  C Brambilla; S Kastanakis; S Knight; K Cunningham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

5.  Increased peritoneal permeability in patients with peritonitis undergoing continuous ambulatory peritoneal dialysis.

Authors:  M E McIntosh; W G Smith; B J Junor; G Forrest; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  No Development of Imipenem Resistance in Pneumonia Caused by Escherichia coli.

Authors:  Josef Yayan; Beniam Ghebremedhin; Kurt Rasche
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

7.  No Resistance to Penicillin, Cefuroxime, Cefotaxime, or Vancomycin in Pneumococcal Pneumonia.

Authors:  Josef Yayan; Beniam Ghebremedhin; Kurt Rasche
Journal:  Int J Med Sci       Date:  2015-11-22       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.